Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-V and COAST-W trials for Ankylosing Spondylitis (AS)
Shots:
- The two P-III trials i.e. COAST-V (N=341) & COAST-W (N=316) involves assessing of Taltz (80/160 mg- q4w/q2w) SC vs adalimumab- or PBO in patients with AS never undergone bDMARD drug and intolerant to TNF inhibitors respectively
- COAST-V and COAST-W Results: @16 wks.: ASAS40 (48%- 25%; 52% -31% vs 18%- 13%); ASAS20 (64%- 48%; 69%- 47% vs 40%- 25%); BASDAI50 (42%- 43% vs 17%): (-2.2 ± 0.2- -2.1 ± 0.2 & -0.9 ± 0.2); MRI Spine SPARCC CFB: (-11.0- -11.0; -9.6- -9.6 vs -1.5- -1.5)
- Taltz is a mAb binds with interleukin 17A (IL-17A)- and is approved treatment for PA & moderate-to-severe plaque psoriasis in adults. Lilly plans to file BLA under the US FDA with reference to above results in AS/radiographic axSpA
/ article | Ref: Eli Lilly | Image: Bolon
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com